402 related articles for article (PubMed ID: 32776299)
1. Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.
Laveti V; Balakrishnan D; Rani PK; Mohamed A; Jalali S
Int Ophthalmol; 2020 Dec; 40(12):3539-3545. PubMed ID: 32776299
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Outcomes Between Combined Sparing Laser Photocoagulation and Intravitreal Bevacizumab Treatment Versus Conventional Laser Photocoagulation in Aggressive Posterior Retinopathy of Prematurity.
Ittarat M
J Pediatr Ophthalmol Strabismus; 2021; 58(5):292-297. PubMed ID: 34180288
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
[TBL] [Abstract][Full Text] [Related]
7. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
8. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
9. Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7.
Chhablani J; Rani PK; Balakrishnan D; Jalali S
Semin Ophthalmol; 2014 Jul; 29(4):222-5. PubMed ID: 24117452
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
11. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
[TBL] [Abstract][Full Text] [Related]
12. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
[TBL] [Abstract][Full Text] [Related]
14. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
Sindal MD; Nagesha CK; Yadav D; Fazal R
Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
[TBL] [Abstract][Full Text] [Related]
15. [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab].
Andrassi-Darida M; Mais C; Stieger K; Lorenz B
Klin Monbl Augenheilkd; 2020 Dec; 237(12):1468-1476. PubMed ID: 31770787
[TBL] [Abstract][Full Text] [Related]
16. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
[TBL] [Abstract][Full Text] [Related]
17. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
Kıran Yenice E; Petriçli İS; Kara C
Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
[TBL] [Abstract][Full Text] [Related]
18. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
19. The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity.
Akdogan M; Cevik SG; Sahin O
Indian J Ophthalmol; 2019 Jun; 67(6):879-883. PubMed ID: 31124508
[TBL] [Abstract][Full Text] [Related]
20. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
Dikci S; Ceylan OM; Demirel S; Yılmaz T
Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
